Precipio stock falls 2.29 percent as Q2 revenue rises 24.18 percent

Published on 10/07/2026 at 03:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Precipio stock fell to USD 23.45 on October 6, 2026, while second-quarter revenue rose 24.18 percent year over year. EPS was negative USD 0.12.

PRPO, US74019L6020, Illustration mit AI erstellt.

Precipio stock (ISIN US74019L6020) was last at USD 23.45 on Nasdaq on October 6, 2026, at 4:00 p.m. ET, down 2.29 percent from the prior close. The latest second-quarter figures show revenue of USD 7.021 million, up 24.18 percent year over year, according to ScanX in its August 15, 2026 report.

Revenue growth meets earnings pressure

The revenue figure refers to the quarter ended June 30, 2026. Precipio's sales increased from USD 5.654 million in the year-earlier quarter, while diluted earnings per share moved from a profit of USD 0.05 to a loss of USD 0.12, according to ScanX. The comparison leaves investors with a clear split between stronger sales and weaker per-share profitability.

The reported figures also put the quarter in the context of Precipio's operating model. The company combines pathology services with diagnostic products, using its laboratory work to identify needs and validate solutions before commercial rollout.

Stock remains below its yearly high

At USD 23.45, the stock stood USD 10.18 below its 52-week high of USD 33.63 and USD 7.05 above its 52-week low of USD 16.40. The same October 6 market reading showed an intraday range of USD 23.24 to USD 24.27, with volume of 18,162 shares.

Precipio's market capitalization was USD 41.8 million as of October 6, 2026. That small-cap valuation makes the contrast between revenue growth and earnings performance especially important, because a single quarter can materially alter how the market weighs scale, cash generation and operating costs.

Diagnostics platform anchors the story

Precipio describes its platform as a way to reduce laboratory misdiagnosis by combining academic expertise, diagnostic technology and clinical information for physicians and patients. The investor-relations page lists hematopathology services among its products and services and presents the business as focused on clinically impactful cancer diagnostic technologies, according to Precipio.

Precipio stock trades at USD 23.45

Precipio stock was last at USD 23.45 on Nasdaq on October 6, 2026, at 4:00 p.m. ET, with the daily change at negative 2.29 percent. The market capitalization was USD 41.8 million on that date.